4 October 2023:

Initial results from the phase 2 clinical trial “The Diabetes Virus Detection and Intervention Trial” were published in Nature Medicine today. This investigator-initiated trial is evaluating the effect of a combination of pleconaril and ribavirin on the progression of Diabetes type 1 in newly diagnosed children. The trial, that is still ongoing, is conducted in collaboration with investigators in Norway and Denmark.

https://www.nature.com/articles/s41591-023-02576-1.pdf

12 September 2023:

The two first subjects were dosed in Curovirs’ second Phase 1 clinical trial with CUR-N399.

22 March 2022:

Curovir has successfully completed its first clinical trial with CUR-N399.

3 August 2021:

The two first subjects dosed in first-in-human clinical trial with CUR-N399.
The first two healthy volunteers in the first cohort of Curovir’s first clinical trial with CUR-N399 were dosed today. The trial will evaluate the safety and pharmacokinetics of single and repeated ascending doses of CUR-N399. One cohort with healthy elderly (≥65 years) volunteers has been included in addition to the younger (18-55 years) study participants. The clinical phase of the trial is scheduled to be completed in January 2022.

31 March 2021:

Curovir receives in funding from The Swedish Innovation Agency (Vinnova), Swelife and Medtech4health
Curovir and its partners Umeå University and Sahlgrenska University Hospital receives 1.8 million SEK in the call “Collaborative projects for better health”. The application covered development of a formulation to use CUR-N399 in children and confirmation of initial indications of antiviral effect against respiratory syncytial virus, in addition to its effect on enterovirus.

7 October 2020:

Curovir receives funding from the Swedish Innoviation Agency (Vinnova)
Curovir and its project partner Sahlgrenska University Hospital receives 5 million SEK in the call: “Innovations in the wake of the crisis, Health innovation projects to ameliorate the effects of the covid-19 pandemic”. The application was titled: “A new antiviral agent with broad spectrum gives better preparedness for the next pandemic” and covered finalization of preclinical toxicology studies with CUR-N399 and a first in human, phase I clinical trial.